

- About
- Message from Alex Gorsky
- Year In Brief
- Sustainability Approach

Progress on Commitments

Better Health for All

Innovation

Our People

Environmental Health

Responsible Business Practice

Appendix

References

Progress on Commitments

Health for Humanity 2020 Goals²

At Johnson & Johnson, we aspire to profoundly change the trajectory of health for humanity. Our **Health for Humanity 2020 Goals**, underpinned by 16 targets, focus our citizenship and sustainability efforts where we believe Johnson & Johnson can achieve the greatest impact. The goals underscore and reflect our long-term commitment to delivering sustainable social, environmental and economic change across our Company and extended value chain by leveraging the power of our people, expertise, and global partnerships.

Achieving our 2020 Goals is integral to Johnson & Johnson’s long-term success. We consider them to be the Key Performance Indicators of our citizenship and sustainability approach and have processes in place to measure and track progress. We report out on our progress annually, including independent review and assurance of our progress and associated data.

Following is our Scorecard that provides an update on progress we have made to-date against our 2020 Goals.

Goal			
Develop and deliver innovative, lifechanging solutions to address the world’s major health challenges.			
Target	Progress against 2020 Targets (Cumulative)	Notable	Status
Expand the database documenting the effectiveness, efficacy and safety profile of bedaquiline (SIRTURO) through collaborative efforts to further increase access.	<ul style="list-style-type: none"> ▪ Continued enrolling patients from South Korea in Johnson & Johnson multi-country registry. ▪ Submitted Data Sharing Agreement to the Institutional Review Board of the Government of South Africa for approval to integrate patient data from the South African national database to Johnson & Johnson multi-country registry. 		On Track
Collaborate on Phase 3 trials and make regulatory submissions for rilpivirine LA, the first all-injectable depot regimen for HIV.	In collaboration with ViiV Healthcare, completed recruitment into Phase 3 clinical trials of the all-injectable regimen (cabotegavir LA from ViiV Healthcare and EDURANT [rilpivirine] LA from Janssen).		On Track

About

Message from Alex Gorsky

Year In Brief

Sustainability Approach

Progress on Commitments

Better Health for All

Innovation

Our People

Environmental Health

Responsible Business Practice

Appendix

References

Goal

Deliver innovative healthcare access and training programs that impact a billion lives in underserved areas.*

Target	Progress against 2020 Targets (Cumulative)	Notable	Status
Produce and donate 1 billion doses of VERMOX (mebendazole) to treat >100 million children per year at risk for intestinal worms.**	392 million doses of VERMOX donated in 30 countries with 218 million children having been targeted for treatment.	Since 2006, we cumulatively donated 1.2 billion doses of VERMOX.	On Track
Deliver HIV/AIDS therapy access to a cumulative 130,000 adults and 5,000 children.	38,500 adult patients and 630 pediatric patients received access to HIV/AIDS therapy with the branded and generic versions of PREZISTA, INTELENCE and EDURANT.	<ul style="list-style-type: none"> The estimates of the number of patients receiving access are based on the best available therapy access models developed by our Global Public Health Operations team in collaboration with an external partner. We expect our pediatric numbers to increase over the next few years based on our access activities and addition of more countries. 	On Track
Deliver access to MDR-TB therapy to a cumulative 200,000 patients, potentially curing*** 157,000 people with MDR-TB of the disease.	37,000 patients in 95 countries received access to MDR-TB therapy with SIRTURO (bedaquiline).	<ul style="list-style-type: none"> The territory covered by SIRTURO regulatory activities is home to over 80% of the global MDR-TB treated patient burden worldwide. Based on our global bedaquiline uptake forecast models, built upon publicly available WHO individual treatment numbers, we predict a non-linear rate of growth in bedaquiline use in the next years. As communicated through the product label, SIRTURO requires up to two years of full-course treatment therapy in combination with other TB drugs to observe treatment effectiveness. When we report cure results next year, we will estimate the number of patients cured based on the cure success rate observed in the clinical studies. 	On Track
Together with partners, train 30,000 skilled birth attendants to assist 6 million births.	Together with partners, trained 20,000 birth attendants, who assisted in 400,000 births.		On Track
Support the delivery of 6 million eye care screenings to underserved children and corrective treatments (spectacles) as needed to 100,000 underserved children.	In partnership with Lions Club International, supported delivery of 4.2 million eye care screenings and 53,000 corrective treatments (spectacles) to underserved children.	Progress in 2017 is estimated based on delivery of eye screenings and corrective treatments (spectacles provided) in 2016. Actual 2017 data becomes available after our report data collection cut-off date.	On Track

*"Underserved" refers to populations that are disadvantaged because of ability to pay, ability to access care, ability to access comprehensive healthcare, or other disparities for reasons of race, religion, language group or social status.

**After re-evaluating the progress measurement methodology for this target, we concluded that accurately predicting and measuring the reduction in infection rate is not feasible. Therefore, the target was adjusted to remove reporting on the infection reduction rate.

***The *Lancet Respiratory Medicine*, Volume 3, Issue 3, March 2015, Pages 201-209 establishes the correlation between sputum culture conversion and treatment success. From the randomized clinical study (C208) SIRTURO provided a 78.8% culture conversion rate at 24 weeks versus 57.6% for placebo.

About

Message from Alex Gorsky

Year In Brief

Sustainability Approach

Progress on Commitments

Better Health for All

Innovation

Our People

Environmental Health

Responsible Business Practice

Appendix

References

Goal

Collaborate with government, nonprofit and private sector to foster new models of health that improve economic well-being and healthcare in key emerging markets.

Target	Progress against 2020 Targets (Cumulative)	Notable	Status
<p>Activate signature partnerships/initiatives for five of our largest Consumer brands to promote the health and well-being of people in need around the world.</p>	<p>JOHNSON'S and LISTERINE brands each activated partnerships, including digital marketing, social media, public relations, retail/shopper marketing and packaging activities.</p>	<ul style="list-style-type: none"> Partnerships were activated with Save the Children (JOHNSON'S) and Operation Smile (LISTERINE). These brand-specific initiatives build upon existing longstanding relationships with Save the Children and Operation Smile at the corporate level. 	<p>On Track</p>
<p>Drive policy thought leadership and strategic engagements to expand healthcare access and coverage in at least three emerging markets (including Brazil, China, and India), and lead three to five pilots to demonstrate the results of these efforts.</p>	<ul style="list-style-type: none"> More than 700 engagements conducted with government officials and other partners in Brazil, China, and Mexico. Ongoing and new pilot projects being implemented in China, Mexico, Philippines, Russia and Thailand. 	<ul style="list-style-type: none"> Projects in Mexico and Russia aim to expand universal health coverage. Projects in China, Philippines and Thailand focus on sustainable healthcare coverage models and financing models through private health insurance. The project we piloted in India in 2016 with the State of Telegana on state diabetes care strategy has not been successful and has been halted. 	<p>On Track</p>

- About
- Message from Alex Gorsky
- Year In Brief
- Sustainability Approach

Progress on Commitments

Better Health for All

Innovation

Our People

Environmental Health

Responsible Business Practice

Appendix

References

Goal

Fully integrate sustainable design solutions into our product innovation processes.

Target	Progress against 2020 Targets (Cumulative)	Notable	Status
New and existing products representing 20% of Johnson & Johnson revenue achieved EARTHWARDS recognition for sustainable innovation improvements.	New and existing products representing 14.6% of Johnson & Johnson revenue achieved EARTHWARDS recognition.*	While total revenue from sales of EARTHWARDS-recognized products remained stable, the overall enterprise revenue increased in 2017. As such, the percentage of sales representing EARTHWARDS-recognized products decreased slightly compared with the previous year.	On Track
Increase the recyclability of our Consumer product packaging to 90+% (on a weight basis) via design and partnerships in five key markets where mature recycling infrastructure exists (Canada, France, Germany, UK and U.S). In three other markets where recycling infrastructure is less mature engage in partnerships to advance material recovery and recycling efforts.	<ul style="list-style-type: none"> ▪ Established the baseline of 79% for recyclability in North America. ▪ Established the baseline of 76% for European markets (France, Germany and UK). Because of measurement challenges, the baseline is an estimate based on several assumptions. ▪ Engaged in recycling-related partnerships to advance development of recycling infrastructure in less mature markets: an ongoing partnership in Brazil with two cooperatives; two new partnerships--one India and one South East Asia region. 	This target is currently off-track because we are facing delays in our tube and pump recyclability efforts. We are taking corrective action to improve progress on this target.	Off Track

*Percentage not inclusive of products newly recognized in 2017.

About

Message from Alex Gorsky

Year In Brief

Sustainability Approach

Progress on Commitments

Better Health for All

Innovation

Our People

Environmental Health

Responsible Business Practice

Appendix

References

Goal
Reduce our impacts on climate and water resources.

Target	Progress against 2020 Targets (Cumulative)	Notable	Status
Reduce absolute carbon emissions 20% by 2020, and 80% by 2050.	CO ₂ emissions decreased by 21% globally since 2010 (Scope 1 and Scope 2).		On Track
Produce/procure 35% of electricity from renewable sources by 2020; aspire to power all facilities with renewable energy by 2050.	25% of total electricity consumption generated from renewable sources.		On Track
Conduct a comprehensive water risk assessment at 100% of manufacturing/R&D locations, and implement resource protection plans at the high-risk sites.	38% of all high-risk sites identified in water risk assessment process developed mitigation plans and have budget allocated to start implementation in 2018.	100% of the manufacturing/R&D locations completed the comprehensive water risk assessment in 2016.	On Track

Goal
Collaborate with our suppliers to accelerate environmental and social improvements across the value chain.

Target	Progress against 2020 Targets (Cumulative)	Notable	Status
Enroll suppliers covering 80% of our spend in our Sustainable Procurement Program.	Enrolled suppliers covering approximately 51% of spend in our Sustainable Procurement Program.		On Track
Consistently achieve benchmark spending with U.S. diverse suppliers and small suppliers, and double the number of countries with established supplier diversity and inclusion programs.*	<ul style="list-style-type: none"> Exceeded benchmark diverse supplier spending at 10.3% and benchmark small supplier spending at 19.4% of total U.S. spend. Expanded our supplier diversity and inclusion programs to two additional countries (China and Germany) for a total of 12 countries against the baseline of six. 	The 12 countries outside the U.S. where we have started diverse supplier tracking are: Australia, Belgium, Brazil, Canada, China, Colombia, Germany, Mexico, South Africa, Spain, Switzerland and UK.	On Track

*Total spend represents addressable spend, i.e., products and services that procurement teams can negotiate with suppliers to meet business goals.

- About
- Message from Alex Gorsky
- Year In Brief
- Sustainability Approach

Goal

Empower and engage the Johnson & Johnson family of employees to become the healthiest workforce.

Target	Progress against 2020 Targets (Cumulative)	Notable	Status
Empower and engage employees toward a “personal best” in health and well-being via: training of at least 100,000 employees in the principles of ENERGY FOR PERFORMANCE;* connecting at least 100,000 employees to their health via innovative digital health tools; and providing access to at least 100,000 employees to both fully implemented** healthy eating and fully implemented healthy movement cultures.	<ul style="list-style-type: none"> ▪ More than 33,000 employees completed ENERGY FOR PERFORMANCE training. ▪ 84,000 employees engaged in health and well-being via the use of digital health tools since 2016. ▪ 107,000 and 117,000 employees provided access to 50% implemented healthy eating and healthy movement cultures, respectively. 	<ul style="list-style-type: none"> ▪ 61,000 employees have completed the principles of ENERGY FOR PERFORMANCE training since the start of the program, representing 61% progress against our 2020 target of training 100,000 employees. ▪ Only two years into the Goal period, we have already achieved 84% progress against our 2020 target of connecting 100,000 employees to their health via digital health tools. 	On Track

*We count our 28,000 active employees who completed ENERGY FOR PERFORMANCE training prior to January 1, 2016 towards progress against this target.
 **Defined as 100% implementation of policies, programs and practices for both.

On Track: expected to meet the Goal by 2020
In Progress: so far progressing more slowly than expected; plans are in place to meet the Goal by 2020
Off Track: not progressing as expected; currently at risk of not meeting the Goal by 2020

- Better Health for All
- Innovation
- Our People
- Environmental Health
- Responsible Business Practice
- Appendix
- References